Notice: This company has been marked as potentially delisted and may not be actively trading. Xyratex (XRTX) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsEarningsHeadlinesShort InterestTrends XRTX vs. CLRB, IPA, IMNN, BCTX, ACXP, MYNZ, SNSE, TXMD, FLGC, and TLPHShould you be buying Xyratex stock or one of its competitors? The main competitors of Xyratex include Cellectar Biosciences (CLRB), ImmunoPrecise Antibodies (IPA), Imunon (IMNN), BriaCell Therapeutics (BCTX), Acurx Pharmaceuticals (ACXP), Mainz Biomed (MYNZ), Sensei Biotherapeutics (SNSE), TherapeuticsMD (TXMD), Flora Growth (FLGC), and Talphera (TLPH). These companies are all part of the "pharmaceutical preparations" industry. Xyratex vs. Cellectar Biosciences ImmunoPrecise Antibodies Imunon BriaCell Therapeutics Acurx Pharmaceuticals Mainz Biomed Sensei Biotherapeutics TherapeuticsMD Flora Growth Talphera Cellectar Biosciences (NASDAQ:CLRB) and Xyratex (NASDAQ:XRTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, community ranking, profitability, institutional ownership and media sentiment. Which has more risk and volatility, CLRB or XRTX? Cellectar Biosciences has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Comparatively, Xyratex has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Does the media favor CLRB or XRTX? In the previous week, Cellectar Biosciences had 1 more articles in the media than Xyratex. MarketBeat recorded 1 mentions for Cellectar Biosciences and 0 mentions for Xyratex. Cellectar Biosciences' average media sentiment score of 0.00 equaled Xyratex'saverage media sentiment score. Company Overall Sentiment Cellectar Biosciences Neutral Xyratex Neutral Does the MarketBeat Community believe in CLRB or XRTX? Cellectar Biosciences received 87 more outperform votes than Xyratex when rated by MarketBeat users. However, 63.41% of users gave Xyratex an outperform vote while only 54.85% of users gave Cellectar Biosciences an outperform vote. CompanyUnderperformOutperformCellectar BiosciencesOutperform Votes24354.85% Underperform Votes20045.15% XyratexOutperform Votes15663.41% Underperform Votes9036.59% Do insiders and institutionals hold more shares of CLRB or XRTX? 16.4% of Cellectar Biosciences shares are held by institutional investors. Comparatively, 0.2% of Xyratex shares are held by institutional investors. 3.7% of Cellectar Biosciences shares are held by insiders. Comparatively, 6.9% of Xyratex shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is CLRB or XRTX more profitable? Cellectar Biosciences' return on equity of 0.00% beat Xyratex's return on equity.Company Net Margins Return on Equity Return on Assets Cellectar BiosciencesN/A N/A -191.22% Xyratex N/A -146.27%-86.83% Which has stronger valuation & earnings, CLRB or XRTX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCellectar BiosciencesN/AN/A-$42.77M-$1.72-0.18XyratexN/AN/A-$2.16MN/AN/A Do analysts prefer CLRB or XRTX? Cellectar Biosciences presently has a consensus price target of $17.67, suggesting a potential upside of 5,526.33%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Cellectar Biosciences is more favorable than Xyratex.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cellectar Biosciences 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Xyratex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryCellectar Biosciences beats Xyratex on 8 of the 12 factors compared between the two stocks. Get Xyratex News Delivered to You Automatically Sign up to receive the latest news and ratings for XRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XRTX vs. The Competition Export to ExcelMetricXyratexPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.58M$7.05B$5.84B$9.14BDividend YieldN/A2.75%4.75%3.86%P/E RatioN/A6.1426.7919.19Price / SalesN/A268.26435.4570.88Price / CashN/A65.6738.0134.83Price / Book0.356.707.644.62Net Income-$2.16M$138.98M$3.19B$246.06M Xyratex Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XRTXXyratexN/A$0.82-13.2%N/A-68.6%$3.58MN/A0.00N/AHigh Trading VolumeCLRBCellectar Biosciences1.9646 of 5 stars$0.29+3.5%$17.67+5,975.2%-90.6%$13.40MN/A-0.1710Analyst ForecastIPAImmunoPrecise Antibodies2.9832 of 5 stars$0.42-5.0%$5.00+1,085.4%-77.6%$13.10M$18.16M-0.5480News CoverageIMNNImunon2.3161 of 5 stars$0.90flat$20.50+2,177.8%+62.5%$13.05M$500,000.00-0.4830Analyst ForecastNews CoverageGap UpBCTXBriaCell Therapeutics2.4393 of 5 stars$4.35+13.6%$32.00+635.6%-91.7%$12.82MN/A-0.338ACXPAcurx Pharmaceuticals3.2114 of 5 stars$0.74-2.0%$12.00+1,517.3%-75.0%$12.64MN/A-0.683Gap UpMYNZMainz Biomed2.8207 of 5 stars$6.04-7.5%$67.00+1,009.3%-84.9%$12.08M$900,000.00-0.0930News CoverageGap UpHigh Trading VolumeSNSESensei Biotherapeutics4.4745 of 5 stars$0.48-1.9%$4.33+810.4%-40.4%$11.97MN/A-0.4040Positive NewsTXMDTherapeuticsMD0.4495 of 5 stars$1.03flatN/A-42.5%$11.88M$1.30M0.00420Gap UpFLGCFlora Growth1.7654 of 5 stars$0.82-2.2%$5.00+507.5%-13.4%$11.87M$64.15M0.00280TLPHTalphera2.5559 of 5 stars$0.65+2.7%$4.33+568.7%-54.5%$11.04M$650,000.00-0.9419 Related Companies and Tools Related Companies CLRB Alternatives IPA Alternatives IMNN Alternatives BCTX Alternatives ACXP Alternatives MYNZ Alternatives SNSE Alternatives TXMD Alternatives FLGC Alternatives TLPH Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:XRTX) was last updated on 2/23/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredNvidia > DeepSeekEveryone's getting it all wrong … Sure, DeepSeek's reveal caused AI stocks to tumble … But, in the long ...Weiss Ratings | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xyratex Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Xyratex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
